What Vyrsa Technologies does

Vyrsa Technologies is a medical device company specializing in sacroiliac (SI) joint fusion technologies, founded in 2021 and headquartered in King of Prussia, Pennsylvania. The company developed an FDA 510k-cleared implant portfolio anchored by the Nevro1™ (originally branded V1) implant, which uses proprietary integrated lateral transfixation technology with self-deploying titanium anchors to provide axial and rotational stability of the SI joint through a minimally invasive posterior approach. The portfolio was expanded to include NevroPro™ (a custom cortical allograft implant using a novel inferior inlet approach) and NevroFix™ (lateral fixation screws), enabling a comprehensive hybrid surgical technique that combines articular decortication, fixation, and compression. The underlying technology is backed by a 2+ year biomechanics study involving 24 cadaveric trials, 30 motion measurements, and 100k cyclical loads, conducted in collaboration with the FDA. Clinical evidence cites 73% mean pain reduction and 83% clinically significant improvement across a systematic review of 17 studies covering 1,227 patients.

Vyrsa generated revenue through hardware sales of FDA-cleared implants and surgical systems to healthcare providers under a sales-led go-to-market model targeting orthopedic surgeons, neurosurgeons, and pain management specialists performing SI joint fusion procedures. Distribution ran through medical device sales channels including direct hospital sales and physician-directed device ordering, supplemented by medical conferences, physician education programs, peer-reviewed clinical publications, and professional referral networks. The company held a worldwide exclusive license from Camber Spine for the foundational transfixation IP and operated with 11-50 employees. In November 2023, Vyrsa was acquired by Nevro Corp, a publicly traded medical technology company focused on chronic pain, integrating Vyrsa's SI joint fusion portfolio alongside Nevro's HFX 10 kHz Therapy platform.

Name

Vyrsa Technologies

Legal name

VYRSA Technologies

Website

https://vyrsatech.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

11–50 employees

Short description

Vyrsa Technologies is a medical device company that develops FDA-cleared sacroiliac joint fusion implants — including the Nevro1™, NevroPro™, and NevroFix™ systems — for orthopedic surgeons, neurosurgeons, and pain management specialists treating chronic SI joint pain. Acquired by Nevro Corp in November 2023.

Ownership category

akta.pro rank

Product category

Spine Surgical Implants

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC)

akta.pro secondary industries

Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB), 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)

Keywords

• Sacroiliac joint fusion
• Minimally invasive spine surgery
• Orthopedic medical devices
• SI joint implants
• Chronic pain treatment

Headquarters

HQ city

King Of Prussia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: Vyrsa Technologies generates revenue through the sale of FDA-cleared sacroiliac joint fusion implants and surgical systems to healthcare providers and hospitals. The company operates as a medical device manufacturer serving the spine surgery market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Vyrsa Technologies develops and sells FDA 510k-cleared medical devices for minimally invasive sacroiliac (SI) joint fusion surgery. The core product portfolio includes the Nevro1™ titanium implant with integrated lateral transfixation technology, the NevroPro™ cortical allograft implant using a novel inferior inlet approach, and NevroFix™ lateral fixation screws. These implants are sold to orthopedic surgeons, neurosurgeons, and pain management specialists for the treatment of chronic SI joint pain and degenerative sacroiliitis.

Product overview

Vyrsa Technologies offers a portfolio of FDA-cleared medical devices for sacroiliac (SI) joint fusion surgery. The core product lineup includes Nevro1™ (a titanium implant with lateral transfixation technology), NevroPro™ (a custom cortical allograft implant using an inferior inlet approach), and NevroFix™ (lateral fixation screws). The company was acquired by Nevro Corp in November 2023 and operates as part of Nevro's portfolio of chronic pain treatment solutions.

Differentiator

Problem solved

Functional benefit

Brands

• Nevro1™: FDA 510k-cleared sacroiliac joint fusion implant featuring integrated lateral transfixation technology, formerly known as V1 implant
• NevroPro™
• NevroFix™

Products and services

• Nevro1™ SI Joint Fusion System FDA 510k-cleared sacroiliac joint fusion implant featuring integrated lateral transfixation technology with self-contained, deployable titanium anchors that transfix the sacrum and ilium for immediate axial and rotational stability, sold to orthopedic surgeons, neurosurgeons, and pain management specialists for minimally invasive SI joint fusion.
• NevroPro™ SI Fusion System First MIS posterior allograft SI fusion system designed for comprehensive decortication of the SIJ articular surface using a novel inferior inlet approach; custom bone allograft implant offered in multiple sizes for variable patient anatomy, sold to spine surgeons.
• NevroFix™ Lateral Fixation Screws Lateral sacroiliac joint fixation screws designed to provide superior compression in comparison to other threaded fixation implants, sold as part of the SI joint fusion portfolio to spine surgeons.

Quantifiable outcome

• 73% mean pain reduction post-fusion
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and major.

• Nevro CorpcoreStrategic or Co-development Partner · 1 November 2023In November 2023, Nevro Corp acquired Vyrsa Technologies to strengthen its minimally invasive treatment offerings for sacroiliac joint fusion. The acquisition brought VYRSA's FDA-cleared V1 implant technology under Nevro's portfolio.
• FDAcoreStrategic or Co-development PartnerComprehensive 2+ year biomechanics analysis performed in collaboration with the FDA to establish effective stabilization of the SI joint. This collaboration led to FDA 510k clearance in Q4 2022.
• Camber SpinecoreOEM/ Whitelabel/ Licensing PartnerVYRSA Technologies acquired worldwide exclusive license for patented sacroiliac joint fusion technology with integrated lateral transfixation from Camber Spine under the name VYRSA V1.
• Allegheny Health Network - Spine Research LabmajorStrategic or Co-development PartnerBiomechanics testing facility located at Allegheny Singer Research Institute, Department of Neuroscience. Principal Investigator: Boyle Cheng, PhD, Professor of Neurosurgery at Drexel University College of Medicine and Director of Neurosurgical & Spine Research at Allegheny General Hospital.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Stryker: Stryker's spine and orthopedic trauma divisions offer a broad range of fusion implants, fixation, and biologics used in spine and pelvic surgery. As a diversified medtech incumbent, it overlaps with Vyrsa's hospital customer base and procedural categories.
• Medtronic: Medtronic is the largest spine hardware incumbent with broad fusion, fixation, and biologics portfolios. Its spine division targets the same orthopedic and neurosurgery call points as Vyrsa, making it a broad incumbent peer despite not specializing in SI joint fusion.
• Orthofix Medical: Orthofix offers spine hardware, biologics, and orthopedic solutions targeting the same hospital/surgeon channels as Vyrsa/Nevro. It is a broad incumbent in spine fusion and motion preservation procedures relevant to the SI joint patient population.
• Globus Medical: Globus Medical (now including NuVasive) is one of the largest spine hardware companies with a broad portfolio including SI joint fusion offerings. It competes indirectly with Vyrsa/Nevro through comprehensive spine surgery solutions sold to the same surgeon base.
• Boston Scientific: Boston Scientific operates a meaningful spine pain franchise (via Vertiflex and other acquisitions) targeting overlapping pain-management and spine call points. It serves as a broad incumbent peer across the chronic pain patient pathway Vyrsa addresses.

Direct peers

• SI-Bone: SI-Bone pioneered the MIS sacroiliac joint fusion market with its iFuse Implant System and remains the dominant category-defining competitor to Vyrsa/Nevro1. Both companies target the same spine/pain physician call point with transiliac/triangular titanium implants for SI joint fusion.
• Camber Spine: Camber Spine is the original developer of the integrated lateral transfixation technology that Vyrsa exclusively licensed for the Nevro1/V1 implant, and continues to develop SI joint and other spine technologies. It is directly comparable as the originating IP holder and an active SI joint fusion peer.

Emerging players

• PainTEQ: PainTEQ markets the LinQ minimally invasive SI joint fusion system, directly competing with Nevro1 in the same procedure category with a similar posterior allograft approach to Vyrsa's NevroPro. It is an emerging focused competitor in MIS SI joint stabilization.
• Alphatec Holdings: Alphatec is a growth-oriented spine company focused on procedural innovation in fusion and lateral approaches. It is comparable as an emerging focused spine hardware player competing for the same surgeon mindshare in adjacent procedural categories to Vyrsa's SI joint portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vyrsa

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vyrsa Technologies